SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 11, 2000
AMERICAN BIOGENETIC SCIENCES, INC.
(Exact Name Of Registrant As Specified In Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
0-19041 11-2655906
(Commission File Number) (I.R.S. Employer Identification No.)
1375 Akron Street, Copiague, New York 11726
(Address of Principal Executive Offices) (Zip Code)
(631)789-2600
(Registrant's Telephone Number, Including Area Code)
<PAGE>
Item 5.Other Events.
On July 11, 2000, American Biogenetic Sciences, Inc. ("ABS")
announced that it has received notice that the NASDAQ Listing and
Hearing Review Council had reversed the January 7, 2000 decision
of the NASDAQ Listing Qualification Panel and, based upon events
occurring after the Panel decision, determined that ABS should be
afforded listing on the NASDAQ SmallCap Market.
The NASDAQ SmallCap Market listing took effect on July 11,
2000. ABS will continue to trade under the symbol "MABA."
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned, thereunto duly authorized.
AMERICAN BIOGENETIC SCIENCES, INC.
Dated: July 27, 2000 By: /S/ Josef C. Schoell
Josef C. Schoell,
Vice President - Finance and
Chief Financial Officer
